Pathological investigation of thromboembolism in the obstetrics and gynecology disorder

Pathological investigation of thromboembolism in the obstetrics and gynecology disorder - Pathological investigation of thromboembolism in the obstetrics and gynecology disorder (PAINT Study)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000020759

Enrollment

600

Registered

2016-01-27

Start date

2016-01-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Thromboembolism

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Group A:Patients with the history of thromboembolism 1.Patients of obstetrics and gynecology with the history of thromboembolism (deep vein thrombosis or pulmonary embolism). 2.Patients providing the written informed consent. 3.Patient with 20 years or older at the date of informed consent. Group B:Patients without the history of thromboembolism 1.Patients without the history of thromboembolism in obstetrics and gynecology 2.Patients providing the written informed consent. 3.Patient with 20 years or older at the date of informed consent. Group C:Normal female subjects 1.Normal female subjects in human genome/gene analysis research "Pathological Investigation of the factor of thromboembolism peculiar in Asian" conducted at Faculty of Nutritional Science, Nakamura Gakuen University. 2.Patient with 20 years or older at the date of informed consent.

Exclusion criteria

Exclusion criteria: Group A:Patients with the history of thromboembolism 1.Patients with pregnant. 2.Patients with post partum within 28 days.Patients within 28 days after surgery (exclude surgeries less than 30 minutes). Group B:Patients without the history of thromboembolism 1.Patients with pregnant. 2.Patients with post partum within 28 days.Patients within 28 days after surgery (exclude surgeries less than 30 minutes). 4.Patients with anti coagulant therapy (eligible if low-molecular-weight heparin is available more than 2 weeks before collecting blood). 5.Patients who initiated the sex steroid hormone therapy within 3 months. Group C:Normal female subjects The information from human genome/gene analysis research"Pathological Investigation of the factor of thromboembolism peculiar in Asian" in Faculty of Nutritional Science,Nakamura Gakuen University is secondarily used. 1.Patients with hormonal therapy. 2.Patients with pregnant. 3.Patients with malignant disease. 4.Patients with anti coagulant therapy (eligible if low-molecular-weight heparin is available more than 2 weeks before collecting blood).

Design outcomes

Primary

Measure	Time frame
Frequency of protein S gene mutation	—

Secondary

Measure	Time frame
Correlation between protein S gene mutation and protein S specific- activity, correlation among other parameters of coagulation system, hormone level and protein S-specific activity.	—

Countries

Japan

Contacts

Public ContactNatsuko Yokota and Katsuko Egashira

Kyushu University Hospital Department of Obstetrics and Gynecology

natsuko.yokota.192@s.kyushu-u.ac.jp092-642-5395

Outcome results